Treating MAS

Treating macrophage activation syndrome (MAS)

When managing patients with MAS, stabilizing the patient by controlling the widespread hyperinflammation is critical. However, it is also important to try to minimize side effects of broad-spectrum medications used to control their hyperinflammation.1

Treatment for MAS with Still's disease has 2 urgent goals2,3:

Setting sliders icon

Stabilize the patient

Control hyperinflammation to prevent irreversible organ damage

Downward arrow icon

Minimize treatment toxicities

Reduce negative effects of broad-spectrum medications

High-dose glucocorticoid pulse therapy produces an inadequate response in:

Pediatric patient icon

up to 33%

of pediatric patients4

AND

Adult patient icon

up to 80%

of adult patients5-7,*

Current MAS treatment challenges

While high-dose glucocorticoids are typically the first-line therapy for patients with MAS, there are various risks associated with steroid use—especially in pediatric patients. Patients receiving steroids may experience dose-dependent side effects such as hyperglycemia, hypertension, myopathy, psychosis, growth suppression, reductions of bone density, and increased bone fracture rate.1

There has been a critical need for a targeted therapy that can halt the cytokine storm and control hyperinflammation.1

*According to data from individual centers.

PREVIOUS MAS > IFNγ in MAS
NEXT About Gamifant > How Gamifant Works